Volatile compounds released by the bacteria Pseudomonas aeruginosa fuel the growth of a fungal pathogen found in lung infections in cystic fibrosis…
Articles by Daniela Semedo, PhD
Nivalis Therapeutics, Inc., recently announced an expanded clinical development plan for N91115, the company’s first-in-class stabilizer of the cystic fibrosis…
An innovative research center providing tailored physical activity and exercise regimens for young people with cystic fibrosis (CF) has been launched with support…
Savara Pharmaceuticals recently announced that it has closed a $20 million Series C financing round, which will be used to advance a…
As part of the annual “March on the Hill” event in Washington, D.C., sponsored by the Cystic Fibrosis Foundation, Texas…
XENiOS, a privately held medical device company specializing in minimally invasive lung-and-heart assistance, recently announced it has invested $2.6 million in…
Vertex Pharmaceuticals Incorporated recently announced that it has received a Complete Response Letter from the U.S. Food and Drug Administration (…
Arch Biopartners, Inc, announced that it recently submitted an orphan drug designation application to the European Medicines Authority (EMA)…
Parents of a child born with a severe genetic condition such as cystic fibrosis (CF) are greatly affected by their…
The Mayo University Hospital in Ireland has a new €1.4 million day care center for young cystic fibrosis (CF) patients, a…